Get the Stockscreener App
15.61
1.84%
-0.065
Corbus Pharmaceuticals Holdings Inc stock is traded at $15.61, with a volume of 26,993.
It is down -1.84% in the last 24 hours and up +60.57% over the past month.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$15.54
Open:
$15.54
24h Volume:
26,993
Relative Volume:
0.20
Market Cap:
$187.44M
Revenue:
$1.54M
Net Income/Loss:
$-38.70M
P/E Ratio:
-3.3415
EPS:
-4.67
Net Cash Flow:
$-36.86M
1W Performance:
+5.06%
1M Performance:
+60.57%
6M Performance:
+152.55%
1Y Performance:
-18.78%
1-Day Range:
$15.00
$15.86
1-Week Range:
$13.40
$16.97
52-Week Range:
$4.64
$20.77
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
15.29 | 190.45M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.64 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.22 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.01 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.45 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
How to build a dashboard for Corbus Pharmaceuticals Holdings Inc. stock2025 Biggest Moves & Verified Entry Point Signals - newser.com
Visual analytics tools that track Corbus Pharmaceuticals Holdings Inc. performanceJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com
What analysts say about Corbus Pharmaceuticals Holdings Inc 3371 stockBull Market Opportunities & Free Real-Time Trading Signals - earlytimes.in
Can Corbus Pharmaceuticals Holdings Inc. (3371) stock deliver strong annual returnsMarket Performance Report & Verified Short-Term Plans - newser.com
Is Corbus Pharmaceuticals Holdings Inc. reversing from oversold territoryTake Profit & Long-Term Capital Growth Strategies - newser.com
Can Corbus Pharmaceuticals Holdings Inc. hit a new high this monthAnalyst Upgrade & Proven Capital Preservation Methods - newser.com
Is a relief rally coming for Corbus Pharmaceuticals Holdings Inc. holdersQuarterly Growth Report & Verified Short-Term Trading Plans - newser.com
Is Corbus Pharmaceuticals Holdings Inc. stock reversal real or fakeJuly 2025 Breakouts & Expert Verified Stock Movement Alerts - newser.com
Corbus Pharmaceuticals' (CRBP) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
How Corbus Pharmaceuticals Holdings Inc. (3371) stock valuation compares with sector2025 Earnings Surprises & Daily Entry Point Trade Alerts - newser.com
After-Hours Surge: Turn Therapeutics Rockets 134% Post-Close On Nasdaq Debut; Biotech Stocks Rally - RTTNews
Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium - GlobeNewswire
Oct 9 Fireside Chat 10:00AM ET — Corbus CEO Yuval Cohen to Present at Piper Sandler Virtual Oncology Symposium - Stock Titan
What analysts say about Corbus Pharmaceuticals Holdings Inc stockMarket Capitalization Trends & Affordable Trading Growth - earlytimes.in
Corbus Pharmaceuticals Holdings Inc. stock outlook for YEARAnalyst Upgrade & Safe Entry Zone Tips - newser.com
Best data tools to analyze Corbus Pharmaceuticals Holdings Inc. stockQuarterly Risk Review & Daily Oversold Bounce Ideas - newser.com
Published on: 2025-10-05 06:30:04 - newser.com
Is Corbus Pharmaceuticals Holdings Inc. stock gaining market share2025 Risk Factors & Free Long-Term Investment Growth Plans - newser.com
Published on: 2025-10-05 03:14:17 - newser.com
Published on: 2025-10-05 02:56:16 - newser.com
Can Corbus Pharmaceuticals Holdings Inc. stock maintain operating margins2025 AllTime Highs & Low Drawdown Investment Strategies - newser.com
Institutional scanner results for Corbus Pharmaceuticals Holdings Inc.Portfolio Value Summary & Growth Focused Stock Pick Reports - newser.com
These Are The 3 Top-Rated Cannabis Stocks To Buy As Trump Backs CBD - Barchart.com
Oppenheimer lowers Corbus Pharmaceuticals stock price target ahead of ESMO data - Investing.com Canada
What drives Corbus Pharmaceuticals Holdings Inc 3371 stock priceTrade Execution Strategies & Exceptional Growth Investment - earlytimes.in
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Above 50-Day Moving AverageTime to Sell? - MarketBeat
Published on: 2025-09-29 15:28:09 - newser.com
Published on: 2025-09-29 13:16:49 - newser.com
Published on: 2025-09-29 09:08:59 - newser.com
Published on: 2025-09-29 06:04:12 - newser.com
Leading vs lagging indicators on Corbus Pharmaceuticals Holdings Inc. performance2025 Price Action Summary & AI Driven Price Forecasts - newser.com
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Altmeyer Anne | Director |
May 30 '25 |
Sale |
7.25 |
1,392 |
10,096 |
1,391 |
| Smethurst Dominic | Chief Medical Officer |
Mar 06 '25 |
Sale |
6.78 |
6,393 |
43,330 |
70,807 |
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):